The Competition Commission of India approved a proposed corporate restructuring involving a demerger and share exchange between GSK, Pfizer, and Haleon. The Commission found no appreciable adverse effect on Indian competition.
Approval of the Proposed Combination under Section 31(1) of the Act.
This page shows the compact analysis of this judgement. The full analysis — procedural history, issue-by-issue holdings with ratio and obiter, advocates, and paragraph-level evidence for every claim — is being added to the record in batches and will appear here when this judgement has been through it.
COMPETITION COMMISSION OF INDIA
(Combination Registration No. C-2022/05/930)
13 June 2022
Notice under Section 6(2) of the Competition Act, 2002 given by GSK Plc, Pfizer Inc., and Haleon Plc
CORAM:
Mr. Ashok Kumar Gupta Chairperson
Ms. Sangeeta Verma Member
Mr. Bhagwant Singh Bishnoi Member
Order under Section 31(1) of the Competition Act, 2002
Page 1 of 4
Combination Registration No. C-2022/05/930
development, manufacturing and marketing of prescription pharmaceuticals, vaccines and consumer healthcare products.
1 The creation of JVCO was notified to and approved by the Commission on 22 May 2019 (Combination Registration No. C-2019/06/654)
2 The GSKAPL Transaction was notified to and approved by the Commission on 20 January 2022 (Combination Registration No. C-2021/12/887). As submitted, GSKAPL Transaction is yet to be completed.
Combination Registration No. C-2022/05/930
GSK’s intended objective of separation of its consumer healthcare business from the pharmaceuticals/vaccines business, ultimately publicly listing it on the UK bourses.
Page 3 of 4
Combination Registration No. C-2022/05/930
Page 4 of 4
4 provisions across 1 enactments
Competition Commission of India
GSK Plc, Pfizer Inc., and Haleon Plc
Ashok Kumar Gupta
Sangeeta Verma
Bhagwant Singh Bishnoi
As recorded by the court registry
Judgements on the same questions, provisions and authorities, from every court
